Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore
Latest Information Update: 17 Dec 2019
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 17 Jun 2019 New source identified and integrated (European Clinical Trials Database; EudraCT2019-000993-44)
- 24 May 2019 Status changed from active, no longer recruiting to completed.
- 21 Aug 2017 Planned End Date changed from 1 Dec 2018 to 21 Feb 2019.